XNASORGO
Market cap378mUSD
Jan 10, Last price
3.01USD
1D
-3.83%
1Q
-1.95%
IPO
-69.29%
Name
Organogenesis Holdings Inc
Chart & Performance
P/E
76.53
P/S
0.87
EPS
0.04
Div Yield, %
0.00%
Shrs. gr., 5y
13.88%
Rev. gr., 5y
17.49%
Revenues
433m
-3.94%
Net income
5m
-68.16%
CFO
31m
+24.37%
Earnings
Feb 26, 2025
Profile
Avista Public Acquisition Corp. II does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. The company focuses on pursuing businesses in the healthcare industry. Avista Public Acquisition Corp. II was incorporated in 2021 and is based in New York, New York.
IPO date
Dec 02, 2016
Employees
1,030
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 433,140 -3.94% | 450,893 -3.67% | |||||||
Cost of revenue | 420,615 | 428,589 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 12,525 | 22,304 | |||||||
NOPBT Margin | 2.89% | 4.95% | |||||||
Operating Taxes | 5,447 | 4,750 | |||||||
Tax Rate | 43.49% | 21.30% | |||||||
NOPAT | 7,078 | 17,554 | |||||||
Net income | 4,945 -68.16% | 15,532 -83.51% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,422 | ||||||||
BB yield | -0.40% | ||||||||
| Debt | |||||||||
Debt current | 33,936 | 16,246 | |||||||
Long-term debt | 152,760 | 160,567 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,213 | 1,122 | |||||||
Net debt | 82,358 | 74,335 | |||||||
| Cash flow | |||||||||
Cash from operating activities | 30,917 | 24,859 | |||||||
CAPEX | (24,364) | (33,898) | |||||||
Cash from investing activities | (24,364) | (33,898) | |||||||
Cash from financing activities | (5,505) | (2,199) | |||||||
FCF | (20,003) | (15,252) | |||||||
| Balance | |||||||||
Cash | 104,338 | 102,478 | |||||||
Long term investments | |||||||||
Excess cash | 82,681 | 79,933 | |||||||
Stockholders' equity | (40,958) | (45,288) | |||||||
Invested Capital | 454,410 | 433,245 | |||||||
ROIC | 1.59% | 4.04% | |||||||
ROCE | 3.03% | 5.75% | |||||||
| EV | |||||||||
Common stock shares outstanding | 132,747 | 132,383 | |||||||
Price | 4.09 52.04% | 2.69 -70.89% | |||||||
Market cap | 542,934 52.46% | 356,111 -71.17% | |||||||
EV | 625,292 | 430,446 | |||||||
EBITDA | 35,974 | 40,335 | |||||||
EV/EBITDA | 17.38 | 10.67 | |||||||
Interest | 2,190 | 2,009 | |||||||
Interest/NOPBT | 17.49% | 9.01% | |||||||